Drug Profile

L ICON3

Alternative Names: ET 201 - Eikonoklastes Therapeutics; L-ICON3

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ohio State University; Yale University
Developer Eikonoklastes Therapeutics
Class Antineoplastics; Immunoconjugates; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (Parenteral)
02 Dec 2022 L ICON3 is still in preclinical stage for triple negative breast cancer in USA (Eikonoklastes pipeline, November 2022)
22 Nov 2022 Early research in Malignant melanoma in USA (Parenteral) (Eikonoklastes pipeline, November 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com